Analysis of Short-term (Operating) Activity Ratios
Quarterly Data
Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Short-term Activity Ratios (Summary)
IQVIA Holdings Inc., short-term (operating) activity ratios (quarterly data)
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
| Short-term activity ratio | Description | The company |
|---|---|---|
| Receivables turnover | An activity ratio equal to revenue divided by receivables. | IQVIA Holdings Inc. receivables turnover ratio deteriorated from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023. |
| Short-term activity ratio | Description | The company |
|---|---|---|
| Average receivable collection period | An activity ratio equal to the number of days in the period divided by receivables turnover. | IQVIA Holdings Inc. number of days of receivables outstanding deteriorated from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023. |
Receivables Turnover
IQVIA Holdings Inc., receivables turnover calculation (quarterly data)
| Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
| Revenues | 3,736) | 3,728) | 3,652) | 3,739) | 3,562) | 3,541) | 3,568) | 3,636) | 3,391) | 3,438) | 3,409) | 3,298) | 2,786) | 2,521) | 2,754) | 2,895) | 2,769) | 2,740) | 2,684) | 2,688) | 2,594) | 2,567) | 2,563) | |||||||
| Trade accounts receivable and unbilled services, net | 3,227) | 3,139) | 3,063) | 2,917) | 2,640) | 2,679) | 2,619) | 2,551) | 2,330) | 2,276) | 2,361) | 2,410) | 2,414) | 2,371) | 2,634) | 2,582) | 2,514) | 2,401) | 2,461) | 2,394) | 2,298) | 2,172) | 2,250) | |||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||||||||
| Receivables turnover1 | 4.60 | 4.68 | 4.73 | 4.94 | 5.42 | 5.28 | 5.36 | 5.44 | 5.81 | 5.68 | 5.09 | 4.71 | 4.54 | 4.61 | 4.24 | 4.29 | 4.33 | 4.46 | 4.28 | 4.35 | — | — | — | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Receivables Turnover, Competitors2 | ||||||||||||||||||||||||||||||
| AbbVie Inc. | 4.83 | 4.88 | 4.95 | 5.16 | 5.38 | 5.10 | 5.29 | 5.63 | 5.94 | 5.42 | 5.24 | 5.19 | 4.83 | 4.34 | 5.35 | 6.13 | — | — | — | — | — | — | — | |||||||
| Amgen Inc. | 4.17 | 4.34 | 4.34 | 4.46 | 4.60 | 4.62 | 4.81 | 4.96 | 5.11 | 5.39 | 5.41 | 5.36 | 5.81 | 4.31 | 4.55 | 5.47 | — | — | — | — | — | — | — | |||||||
| Danaher Corp. | 6.45 | 6.64 | 6.89 | 6.40 | 7.09 | 6.81 | 6.87 | 6.36 | 6.69 | 6.51 | 6.28 | 5.51 | 5.83 | 5.59 | 5.25 | 5.61 | — | — | — | — | — | — | — | |||||||
| Eli Lilly & Co. | 3.93 | 3.93 | 3.68 | 4.14 | 4.35 | 4.57 | 4.64 | 4.24 | 4.69 | 4.58 | 4.56 | 4.18 | 4.75 | 4.75 | 4.52 | 4.91 | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | 5.68 | 6.43 | 6.43 | 5.65 | 6.16 | 6.60 | 7.18 | 6.01 | 5.95 | 6.34 | 6.43 | 4.98 | 5.83 | 6.84 | 5.73 | 6.18 | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | 5.91 | 5.36 | 5.65 | 5.88 | 6.04 | 5.92 | 6.08 | 6.14 | 6.13 | 6.00 | 5.64 | 6.08 | 5.55 | 5.50 | 5.56 | 5.67 | — | — | — | — | — | — | — | |||||||
| Merck & Co. Inc. | 5.71 | 5.29 | 5.56 | 6.27 | 6.22 | 5.93 | 5.49 | 5.28 | 5.56 | 6.00 | 5.65 | 6.11 | 5.62 | 6.23 | 5.88 | 6.91 | — | — | — | — | — | — | — | |||||||
| Moderna Inc. | 4.68 | 43.53 | 12.88 | 13.31 | 7.61 | 8.25 | 6.89 | 5.57 | 3.48 | 3.03 | 0.60 | 0.14 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 6.18 | 7.62 | 7.55 | 9.16 | 6.21 | 6.68 | 6.99 | 7.08 | 5.81 | 5.23 | 4.70 | 5.28 | 4.29 | 4.96 | 4.93 | 5.93 | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 2.35 | 2.47 | 2.42 | 2.28 | 2.47 | 2.76 | 3.41 | 2.66 | 2.48 | 1.77 | 2.20 | 2.07 | 2.04 | 2.84 | 2.72 | 2.94 | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 5.19 | 5.43 | 5.53 | 5.53 | 5.76 | 5.53 | 5.21 | 4.92 | 7.03 | 6.99 | 6.46 | 5.61 | 5.49 | 5.86 | 5.69 | 5.87 | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2023 Calculation
Receivables turnover
= (RevenuesQ3 2023
+ RevenuesQ2 2023
+ RevenuesQ1 2023
+ RevenuesQ4 2022)
÷ Trade accounts receivable and unbilled services, net
= (3,736 + 3,728 + 3,652 + 3,739)
÷ 3,227 = 4.60
2 Click competitor name to see calculations.
| Short-term activity ratio | Description | The company |
|---|---|---|
| Receivables turnover | An activity ratio equal to revenue divided by receivables. | IQVIA Holdings Inc. receivables turnover ratio deteriorated from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023. |
Working Capital Turnover
IQVIA Holdings Inc., working capital turnover calculation (quarterly data)
| Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
| Current assets | 5,208) | 5,329) | 5,328) | 4,981) | 4,752) | 4,911) | 4,772) | 4,763) | 4,534) | 5,068) | 5,579) | 5,090) | 4,645) | 4,208) | 4,277) | 4,126) | 3,995) | 3,978) | 3,999) | 3,874) | 3,696) | 3,587) | 3,724) | |||||||
| Less: Current liabilities | 6,589) | 6,543) | 6,657) | 5,578) | 5,253) | 5,104) | 5,157) | 5,241) | 4,847) | 4,819) | 4,868) | 4,558) | 4,139) | 3,843) | 3,907) | 3,945) | 3,576) | 3,495) | 3,502) | 3,534) | 3,380) | 3,166) | 3,199) | |||||||
| Working capital | (1,381) | (1,214) | (1,329) | (597) | (501) | (193) | (385) | (478) | (313) | 249) | 711) | 532) | 506) | 365) | 370) | 181) | 419) | 483) | 497) | 340) | 316) | 421) | 525) | |||||||
| Revenues | 3,736) | 3,728) | 3,652) | 3,739) | 3,562) | 3,541) | 3,568) | 3,636) | 3,391) | 3,438) | 3,409) | 3,298) | 2,786) | 2,521) | 2,754) | 2,895) | 2,769) | 2,740) | 2,684) | 2,688) | 2,594) | 2,567) | 2,563) | |||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||||||||
| Working capital turnover1 | — | — | — | — | — | — | — | — | — | 51.93 | 16.90 | 21.35 | 21.65 | 29.97 | 30.16 | 61.26 | 25.97 | 22.17 | 21.19 | 30.62 | — | — | — | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Working Capital Turnover, Competitors2 | ||||||||||||||||||||||||||||||
| AbbVie Inc. | — | — | — | — | — | — | — | — | 130.12 | — | — | — | — | — | 0.97 | 0.98 | — | — | — | — | — | — | — | |||||||
| Amgen Inc. | 0.81 | 0.84 | 0.82 | 3.82 | 2.52 | 3.67 | 4.34 | 3.37 | 2.55 | 5.35 | 2.84 | 2.55 | 1.87 | 1.87 | 3.27 | 3.96 | — | — | — | — | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 10.47 | 5.53 | 5.55 | 8.30 | 5.75 | 4.92 | 6.24 | 3.95 | 4.43 | 4.24 | 4.25 | 3.72 | 2.77 | 3.09 | 2.38 | 2.28 | — | — | — | — | — | — | — | |||||||
| Danaher Corp. | 2.29 | 3.08 | 3.81 | 4.20 | 5.00 | 5.43 | 5.91 | 8.40 | 7.98 | 3.12 | 3.45 | 3.48 | 3.14 | 2.80 | 6.74 | 0.87 | — | — | — | — | — | — | — | |||||||
| Eli Lilly & Co. | 31.79 | 12.21 | 5.77 | 31.84 | 14.71 | 19.45 | 8.19 | 8.33 | 6.73 | 12.14 | 5.21 | 4.93 | 5.45 | 8.85 | 16.68 | 11.54 | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | 6.74 | 84.15 | 9.14 | 8.42 | 8.56 | 6.87 | 6.68 | 8.54 | 7.25 | 7.09 | 7.06 | 5.30 | 1.07 | 1.55 | 1.24 | 1.08 | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | 9.37 | 14.06 | 23.02 | — | 4.88 | 5.02 | 5.57 | 5.95 | 5.97 | 5.93 | 7.26 | 9.44 | 4.32 | 8.83 | 7.85 | 8.81 | — | — | — | — | — | — | — | |||||||
| Merck & Co. Inc. | 6.69 | 8.86 | 5.63 | 5.16 | 5.58 | 6.39 | 6.09 | 7.62 | 6.51 | 6.97 | 84.97 | 109.83 | 7.67 | 6.59 | 17.87 | 8.90 | — | — | — | — | — | — | — | |||||||
| Moderna Inc. | 1.36 | 1.35 | 1.66 | 2.17 | 2.74 | 3.29 | 3.07 | 2.55 | 3.15 | 2.88 | 0.59 | 0.10 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 1.60 | 2.01 | 6.88 | 11.00 | 3.83 | 5.05 | 6.10 | 4.78 | 4.29 | 4.21 | 3.60 | 4.58 | 3.16 | 3.31 | 57.45 | — | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 0.87 | 0.92 | 0.90 | 0.96 | 1.09 | 1.14 | 1.46 | 1.59 | 1.35 | 1.29 | 1.35 | 1.20 | 1.22 | 1.92 | 1.21 | 1.41 | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 4.86 | 7.40 | 10.13 | 5.46 | 5.40 | 6.03 | 6.13 | 5.87 | 2.30 | 3.10 | 3.36 | 2.76 | 2.37 | 2.69 | 3.54 | 4.48 | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2023 Calculation
Working capital turnover
= (RevenuesQ3 2023
+ RevenuesQ2 2023
+ RevenuesQ1 2023
+ RevenuesQ4 2022)
÷ Working capital
= (3,736 + 3,728 + 3,652 + 3,739)
÷ -1,381 = —
2 Click competitor name to see calculations.
Average Receivable Collection Period
IQVIA Holdings Inc., average receivable collection period calculation (quarterly data)
| Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||||||||||||||||||||||||||
| Receivables turnover | 4.60 | 4.68 | 4.73 | 4.94 | 5.42 | 5.28 | 5.36 | 5.44 | 5.81 | 5.68 | 5.09 | 4.71 | 4.54 | 4.61 | 4.24 | 4.29 | 4.33 | 4.46 | 4.28 | 4.35 | — | — | — | |||||||
| Short-term Activity Ratio (no. days) | ||||||||||||||||||||||||||||||
| Average receivable collection period1 | 79 | 78 | 77 | 74 | 67 | 69 | 68 | 67 | 63 | 64 | 72 | 77 | 80 | 79 | 86 | 85 | 84 | 82 | 85 | 84 | — | — | — | |||||||
| Benchmarks (no. days) | ||||||||||||||||||||||||||||||
| Average Receivable Collection Period, Competitors2 | ||||||||||||||||||||||||||||||
| AbbVie Inc. | 76 | 75 | 74 | 71 | 68 | 72 | 69 | 65 | 61 | 67 | 70 | 70 | 76 | 84 | 68 | 60 | — | — | — | — | — | — | — | |||||||
| Amgen Inc. | 88 | 84 | 84 | 82 | 79 | 79 | 76 | 74 | 71 | 68 | 67 | 68 | 63 | 85 | 80 | 67 | — | — | — | — | — | — | — | |||||||
| Danaher Corp. | 57 | 55 | 53 | 57 | 51 | 54 | 53 | 57 | 55 | 56 | 58 | 66 | 63 | 65 | 69 | 65 | — | — | — | — | — | — | — | |||||||
| Eli Lilly & Co. | 93 | 93 | 99 | 88 | 84 | 80 | 79 | 86 | 78 | 80 | 80 | 87 | 77 | 77 | 81 | 74 | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | 64 | 57 | 57 | 65 | 59 | 55 | 51 | 61 | 61 | 58 | 57 | 73 | 63 | 53 | 64 | 59 | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | 62 | 68 | 65 | 62 | 60 | 62 | 60 | 59 | 60 | 61 | 65 | 60 | 66 | 66 | 66 | 64 | — | — | — | — | — | — | — | |||||||
| Merck & Co. Inc. | 64 | 69 | 66 | 58 | 59 | 62 | 66 | 69 | 66 | 61 | 65 | 60 | 65 | 59 | 62 | 53 | — | — | — | — | — | — | — | |||||||
| Moderna Inc. | 78 | 8 | 28 | 27 | 48 | 44 | 53 | 66 | 105 | 120 | 606 | 2,539 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 59 | 48 | 48 | 40 | 59 | 55 | 52 | 52 | 63 | 70 | 78 | 69 | 85 | 74 | 74 | 62 | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 156 | 148 | 151 | 160 | 148 | 132 | 107 | 137 | 147 | 206 | 166 | 177 | 179 | 128 | 134 | 124 | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 70 | 67 | 66 | 66 | 63 | 66 | 70 | 74 | 52 | 52 | 56 | 65 | 66 | 62 | 64 | 62 | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2023 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ 4.60 = 79
2 Click competitor name to see calculations.
| Short-term activity ratio | Description | The company |
|---|---|---|
| Average receivable collection period | An activity ratio equal to the number of days in the period divided by receivables turnover. | IQVIA Holdings Inc. number of days of receivables outstanding deteriorated from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023. |